KDB GLIDE Device for Advanced Excisional Goniotomy Treatment of Glaucome: Now Commercially Available Across the U.S. to Ophthalmic Surgeons

February 17, 2021

KDB GLIDE, a device for advanced excisional goniotomy treatment of glaucoma, was registered with the FDA in October 2020. 

“At New World Medical, we are thrilled to offer surgeons the new KDB GLIDE. The Kahook Dual Blade made goniotomy markedly easier, and now feedback from surgeons who use it every day has guided the development of this smooth, elegant and precise next-generation device,” said Raymond Kong, Chief Commercial Officer at New World Medical. “Surgeons appreciate the enhanced experience, but glaucoma patients are the ultimate recipients of KDB GLIDE’s improvements that allow their surgeons better options for treating their condition.”

Excisional goniotomy is a long-established procedure in which a segment of the diseased trabecular meshwork is removed, which facilitates the flow of aqueous into collector channels of the eye, thus alleviating intraocular pressure. Because goniotomy is appropriate for mild, moderate and severe glaucoma, as a stand-alone procedure or in combination with cataract surgery, more than 4.5 million glaucoma1 patients in the U.S. alone are suitable candidates.

The exceptionally successful Kahook Dual Blade family of devices has set a gold standard as accurate, cost-effective solutions for excisional goniotomy. The device’s proprietary ramp facilitates lifting and stretching the trabecular meshwork, while the dual blades penetrate the trabecular meshwork and create parallel incisions for precise, controlled excision. New features in the KDB GLIDE device reinforce these important strengths: a rounded heel, tapered sides, and smaller footplate deliver optimal interface with the canal of Schlemm, permitting precise excision with the instrument’s proprietary dual blades, even in variable anatomy.

“The advantage of the Kahook Dual Blade always has been that it treats pathways of resistance as it smoothly cleaves two areas of the trabecular meshwork, creating a clean strip that minimizes fibrosis and closure over time,” said Nathan Radcliffe, MD, New York Eye and Ear Infirmary of Mount Sinai, New York. “The KDB GLIDE’s foot plate is uniquely designed to fit into the canal of Schlemm, so it can move even more easily through the canal without causing damage, for a graceful and uncomplicated procedure.”

Blake Williamson, MD, Williamson Eye Center, Baton Rouge, added, “Some studies have shown that the Schlemm canal undergoes morphological changes as people age, including narrowing.2 I’m excited to use the KDB GLIDE because its tapered sides and smaller footplate will enable us to smoothly move the device through the canal and remove tissue cleanly, even in cases where the anatomy is narrow or irregular.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”